Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mevacor OTC Panel Rejection Elicits Third Drug Class Talk

This article was originally published in The Tan Sheet

Executive Summary

A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists

Related Content

Pharmacists’ Regard Grows For OTCs As Rx Alternatives, APhA Officer Says
Von Eschenbach Promotes Behind-The-Counter Drug Class
Future OTC Technologies Will Bring Regulatory Challenges – Gottlieb
UK Pharmacy Zocor Faces “Major Challenges” Communicating Risk Factors
Circulation Articles Question Crestor, Stress Statin Selection Complexity
Hemwall on Mevacor
British Pharmacy-Only Statin Paradigm Immaterial To U.S. Switch – NEJM
UK Zocor Experience Inadequate To Sway FDA Panel On Mevacor
Mevacor Panelists Discuss Rx Formulary, OTC Cost Concerns
Mevacor “Pharmacy Care” Tactic Insufficient To Ensure Compliance – Panel





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts